UK's Arecor Therapeutics 2025 revenue falls due to Tetris Pharma

Arecor Therapeutics

09/02/2026 07:12

Overview

UK biopharma firm's 2025 revenue fell due to Tetris Pharma operations ceasing

Company signed co-development deal with Sequel Med Tech for insulin delivery

Company filed patent for oral peptide delivery platform in Q4 2025

Outlook

Arecor expects continued development of AT278 with Sequel's insulin delivery system

Company aims to enhance oral peptide bioavailability through ongoing non-clinical studies

Arecor filed patent for novel compositions to improve oral peptide delivery

Result Drivers

INSULIN DEVELOPMENT - Significant progress with AT278 insulin, including positive FDA feedback and co-development deal with Sequel Med Tech

ORAL PEPTIDE PLATFORM - Patent filed for improved bioavailability of oral GLP-1, aiming to enhance peptide delivery

REVENUE DECLINE - Revenue fell to £3.1 mln due to cessation of Tetris Pharma operations

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
GBP 3.10 mln
GBP 3.20 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Arecor Therapeutics PLC is GBp275.50, about 255.5% above its February 6 closing price of GBp77.50

Press Release: ID:nRSI1428Sa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)